2. Nghiên cứu mối liên quan giữa đặc điểm trên phim chụp nhũ ảnh và ung thư vú típ Her2 dương tính
Nội dung chính của bài viết
Tóm tắt
Mục tiêu là xác định mối liên quan giữa đặc điểm hình ảnh X-quang tuyến vú và ung thư tuyến vú típ HER2 dương tính. Nghiên cứu mô tả cắt ngang được thực hiện trên 553 bệnh nhân ung thư biểu mô tuyến vú xâm nhập được chụp X-quang tuyến vú số hóa tại Bệnh viện K từ tháng 3/2022 đến tháng 10/2023. Đặc điểm hình ảnh ung thư vú trên X-quang tuyến vú được phân tích, đối chiếu với típ phân tử trên mẫu bệnh phẩm phẫu thuật ung thư vú, theo tiêu chuẩn tại Đồng thuận Gallen 2015. Kết quả cho thấy tỷ lệ ung thư vú HER2 dương tính là 29.1%. Phân tích hồi quy logistics đơn biến và đa biến cho thấy dấu hiệu vôi hóa, bất đối xứng đậm độ và co kéo núm vú làm tăng khả năng HER2 dương tính với odds ratio (OR) lần lượt 13,492, 14,859 và 1,632 (p < 0,05). Ngược lại, tổn thương dạng khối có bờ tua gai làm giảm khả năng HER2 dương tính với OR = 0,483 (p < 0,05).
Chi tiết bài viết
Từ khóa
X-quang tuyến vú, ung thư vú, HER2 dương tính
Tài liệu tham khảo
1. Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. Nov 1 2013; 31(31): 3997-4013. doi:10.1200/jco.2013.50.9984.
2. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (New York, NY). Jan 9 1987; 235(4785): 177-82. doi:10.1126/science.3798106.
3. Loibl S, Gianni L. HER2-positive breast cancer. The Lancet. 2017; 389(10087): 2415-2429. doi:10.1016/S0140-6736(16)32417-5.
4. Swain SM, Baselga J, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. The New England journal of medicine. Feb 19 2015; 372(8): 724-34. doi:10.1056/NEJMoa1413513.
5. Portnow LH, Kochkodan-Self JM, Maduram A, et al. Multimodality Imaging Review of HER2-positive Breast Cancer and Response to Neoadjuvant Chemotherapy. Radiographics: a review publication of the Radiological Society of North America, Inc. Feb 2023; 43(2): e220103. doi:10.1148/rg.220103.
6. Song SE, Bae MS, Chang JM, Cho N, Ryu HS, Moon WK. MR and mammographic imaging features of HER2-positive breast cancers according to hormone receptor status: a retrospective comparative study. Acta Radiol. 2017 Jul; 58(7): 792-799. doi: 10.1177/0284185116673119. Epub 2016 Oct 17. PMID: 27754920.
7. Elias SG, Adams A, Wisner DJ, et al. Imaging features of HER2 overexpression in breast cancer: a systematic review and meta-analysis. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. Aug 2014; 23(8): 1464-83. doi:10.1158/1055-9965.Epi-13-1170.
8. Fowler EE, Sellers TA, Lu B, Heine JJ. Breast Imaging Reporting and Data System (BI-RADS) breast composition descriptors: automated measurement development for full field digital mammography. Medical physics. Nov 2013; 40(11): 113502. doi:10.1118/1.4824319.
9. Jackisch C, Harbeck N, Huober J, et al. 14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts. Breast Care (Basel). Jul 2015; 10(3): 211-9. doi:10.1159/000433590.
10. Waks AG, Winer EP. Breast Cancer Treatment: A Review. JAMA. 2019 Jan 22; 321(3): 288-300. doi: 10.1001/jama.2018.19323. PMID: 30667505.
11. Institute NC. Cancer stat facts: female breast cancer. National Cancer Institute Bethesda, MA; 2020.
12. Hoang TH, Phung Thi HT. 15P HER2-positive breast cancer in a low-middle income country (LMIC): Lack of pathology capability and the urgent need for targeted treatment. Annals of Oncology. 2024; 35: S1410. doi:10.1016/j.annonc.2024.10.035.
13. Shin HJ, Kim HH, Huh MO, et al. Correlation between mammographic and sonographic findings and prognostic factors in patients with node-negative invasive breast cancer. Br J Radiol. Jan 2011; 84(997): 19-30. doi:10.1259/bjr/92960562.
14. Dogan BE, Turnbull LW. Imaging of triple-negative breast cancer. Ann Oncol. Aug 2012; 23 Suppl 6:vi23-9. doi:10.1093/annonc/mds191.
15. Johnson KS, Conant EF, Soo MS. Molecular Subtypes of Breast Cancer: A Review for Breast Radiologists. Journal of Breast Imaging. 2020; 3(1): 12-24. doi:10.1093/jbi/wbaa110 %J Journal of Breast Imaging.
16. Ramírez-Galván, Yazmín & Uribe-Martinez, Minerva & Ponce-Camacho, Marco & Montemayor, Alberto. (2022). Spiculated margin on ultrasound is associated with tumor grade and immunohistochemical profile in breast cancer. Journal of the Mexican Federation of Radiology and Imaging. 1. 10.24875/JMEXFRI.M22000016.
17. Mansour S, Abdullah E, Mohamed EH, Gomaa MMM. Imaging of HER2 detected receptor expression positive breast cancer: from detection to interpretation. Egyptian Journal of Radiology and Nuclear Medicine. 2023/07/14 2023; 54(1): 122. doi:10.1186/s43055-023-01063-4.
18. Liu G, Li Y, Chen SL, Chen Q. Non-mass enhancement breast lesions: MRI findings and associations with malignancy. Annals of translational medicine. Mar 2022; 10(6): 357. doi:10.21037/atm-22-503.
2. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (New York, NY). Jan 9 1987; 235(4785): 177-82. doi:10.1126/science.3798106.
3. Loibl S, Gianni L. HER2-positive breast cancer. The Lancet. 2017; 389(10087): 2415-2429. doi:10.1016/S0140-6736(16)32417-5.
4. Swain SM, Baselga J, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. The New England journal of medicine. Feb 19 2015; 372(8): 724-34. doi:10.1056/NEJMoa1413513.
5. Portnow LH, Kochkodan-Self JM, Maduram A, et al. Multimodality Imaging Review of HER2-positive Breast Cancer and Response to Neoadjuvant Chemotherapy. Radiographics: a review publication of the Radiological Society of North America, Inc. Feb 2023; 43(2): e220103. doi:10.1148/rg.220103.
6. Song SE, Bae MS, Chang JM, Cho N, Ryu HS, Moon WK. MR and mammographic imaging features of HER2-positive breast cancers according to hormone receptor status: a retrospective comparative study. Acta Radiol. 2017 Jul; 58(7): 792-799. doi: 10.1177/0284185116673119. Epub 2016 Oct 17. PMID: 27754920.
7. Elias SG, Adams A, Wisner DJ, et al. Imaging features of HER2 overexpression in breast cancer: a systematic review and meta-analysis. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. Aug 2014; 23(8): 1464-83. doi:10.1158/1055-9965.Epi-13-1170.
8. Fowler EE, Sellers TA, Lu B, Heine JJ. Breast Imaging Reporting and Data System (BI-RADS) breast composition descriptors: automated measurement development for full field digital mammography. Medical physics. Nov 2013; 40(11): 113502. doi:10.1118/1.4824319.
9. Jackisch C, Harbeck N, Huober J, et al. 14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts. Breast Care (Basel). Jul 2015; 10(3): 211-9. doi:10.1159/000433590.
10. Waks AG, Winer EP. Breast Cancer Treatment: A Review. JAMA. 2019 Jan 22; 321(3): 288-300. doi: 10.1001/jama.2018.19323. PMID: 30667505.
11. Institute NC. Cancer stat facts: female breast cancer. National Cancer Institute Bethesda, MA; 2020.
12. Hoang TH, Phung Thi HT. 15P HER2-positive breast cancer in a low-middle income country (LMIC): Lack of pathology capability and the urgent need for targeted treatment. Annals of Oncology. 2024; 35: S1410. doi:10.1016/j.annonc.2024.10.035.
13. Shin HJ, Kim HH, Huh MO, et al. Correlation between mammographic and sonographic findings and prognostic factors in patients with node-negative invasive breast cancer. Br J Radiol. Jan 2011; 84(997): 19-30. doi:10.1259/bjr/92960562.
14. Dogan BE, Turnbull LW. Imaging of triple-negative breast cancer. Ann Oncol. Aug 2012; 23 Suppl 6:vi23-9. doi:10.1093/annonc/mds191.
15. Johnson KS, Conant EF, Soo MS. Molecular Subtypes of Breast Cancer: A Review for Breast Radiologists. Journal of Breast Imaging. 2020; 3(1): 12-24. doi:10.1093/jbi/wbaa110 %J Journal of Breast Imaging.
16. Ramírez-Galván, Yazmín & Uribe-Martinez, Minerva & Ponce-Camacho, Marco & Montemayor, Alberto. (2022). Spiculated margin on ultrasound is associated with tumor grade and immunohistochemical profile in breast cancer. Journal of the Mexican Federation of Radiology and Imaging. 1. 10.24875/JMEXFRI.M22000016.
17. Mansour S, Abdullah E, Mohamed EH, Gomaa MMM. Imaging of HER2 detected receptor expression positive breast cancer: from detection to interpretation. Egyptian Journal of Radiology and Nuclear Medicine. 2023/07/14 2023; 54(1): 122. doi:10.1186/s43055-023-01063-4.
18. Liu G, Li Y, Chen SL, Chen Q. Non-mass enhancement breast lesions: MRI findings and associations with malignancy. Annals of translational medicine. Mar 2022; 10(6): 357. doi:10.21037/atm-22-503.